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See related article on page
1350. In this issue of the Journal, Gillinov and colleagues1 provide us with anothervaluable contribution in the field of mitral valve repair from their largeexperience at The Cleveland Clinic Foundation available for sophisticatedand cutting-edge (ie, Eugene Blackstone) statistical analysis. The superior-ity of mitral valve repair over replacement in patients with degenerativemitral valve disease is now widely held to be true. It would be surprising to
see a single hand raised in a medical audience today if you asked, “Who would
prefer to have his or her own valve replaced instead of repaired?” Intuitively it is
attractive to keep the parts you were born with. Other potential advantages including
better preservation of left ventricular function, avoidance of long-term anticoagu-
lation (mechanical valves) or reoperation (bioprosthetic valves), and improved
survival all favor mitral valve repair as the gold standard.2-5 Should the need for a
concomitant coronary artery bypass procedure change the paradigm? This is the
important question addressed by Gillinov and associates in their analysis of 679
patients with degenerative mitral valve disease and ischemic heart disease under-
going coronary bypass grafting and mitral valve surgery (repair or replacement). It
is not surprising that their data provide further confirmation of the superiority of
mitral valve repair over replacement in terms of survival, the only end point
examined. Impressively, the benefit of mitral valve repair in patients with degen-
erative mitral regurgitation was noted as early as 2 years after the surgical proce-
dure. This important observation reinforces that the necessity for coronary bypass
grafting should not influence our determination to repair rather than replace a
degenerative mitral valve.
The authors were challenged by the retrospective nature of their analysis, which
included patients undergoing surgery over a 3-decade span: (1) Valve replacements
were more prevalent in the early phase of the study, whereas most of the valve
repairs occurred after 1990. (2) Likewise, the use of the internal thoracic artery was
much more common in later patients in their series, who were also more likely to
receive a valve repair. (3) Both replacement and repair procedures underwent
significant evolution during the study period. For example, chordal-sparing tech-
niques in the valve replacement group became routine in the late 1980s, but this was
not specifically determinable in individual patients. Similarly, valve repair tech-
niques evolved over time, and repairs in their most recent experience were surely
improved by the use of annuloplasty prosthetic rings as opposed to annuloplasty
using bovine pericardium or non-annuloplasty techniques. (4) Myocardial preser-
vation techniques also evolved and were surely more effective in the later era. (5)
The understanding of the pathophysiology of mitral regurgitation and definition of
degenerative mitral valve regurgitation also evolved over the study period.
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Craig Miller6 has previously provided an excellent edi-
torial comment in the Journal regarding the statistical chal-
lenges and tools necessary to address the mitral valve repair
versus replacement comparison for patients in retrospective
nonrandomized trials. Many of the issues Miller discussed
are relevant to this article, and we suggest those interested
in the nuances of the statistical art refer to it. In the current
study by Gillinov and associates, time period was used as a
surrogate for chordal-sparing techniques in an attempt to
assess the impact of this advance in the replacement group
(no advantage was statistically realized.) The potential im-
pact of myocardial protection and the evolution of mitral
repair techniques were unfortunately not examined by the
authors. For the remainder of issues mentioned previously,
there is a lot of “Gene-speak,”6 and the authors used so-
phisticated techniques including multivariable propensity
matching and multivariable, multiphase hazard function
analysis to examine factors associated with valve repair or
replacement and risk factors for death.7,8
It is interesting to note the confusing terminology, typical
of the literature, used by the authors to define degenerative
mitral valve disease. Carpentier9 has affectionately referred
to the usage of multiple terminologies to identify patients
with degenerative disease as the “Babel syndrome,” for
example, “myxomatous degeneration,” “floppy leaflets,”
“billowing leaflets,” and “leaflet prolapse.” It is much more
useful to think about mitral valve disease in terms of his
pathophysiologic triad that includes the type of valve dys-
function, the lesions, and the etiology.9 Valve dysfunction
correlates to Carpentier’s functional classification (see Fig-
ure 1). Patients with degenerative mitral valve disease most
commonly have type II dysfunction, which corresponds to
the overriding of the free edge of the leaflet above the plane
of the mitral annulus during systole (leaflet prolapse). As-
sociated annular dilation is a common finding in these
patients; however, isolated annular dilatation (type I dys-
function) with normal motion of both leaflets has also been
reported. Of note, we have not observed leaflet restriction
(type III dysfunction) in patients with degenerative disease
due to an “abnormal chordal mesh” of the posterior leaflet
as described by the authors. Lesions most commonly re-
sponsible for valve dysfunction in degenerative mitral valve
disease include chordal elongation and chordal rupture.
Etiologies of degenerative mitral valve disease include fi-
broelastic deficiency (first described by Carpentier), Barlow
disease (characterized by myxoid degeneration), and
Marfan disease.10 Fibroelastic deficiency is most common
in elderly patients with a relatively short history of valve
dysfunction. Intraoperative analysis typically shows trans-
parent leaflets with no excess tissue except in the prolapsing
segment, and elongated, thin and frail, often ruptured, chor-
dae. The annulus is often dilated, and may be calcified. In
contrast, Barlow disease appears early in life, and patients
typically have a long history of a systolic murmur. The
valve leaflets are typically thick with marked excess tissue.
The chordae are thickened, elongated, and may be ruptured.
Papillary muscles are also occasionally elongated. The an-
nulus is dilated and sometimes calcified. Marfan disease
with mitral regurgitation is characterized by excess leaflet
tissue, which may be thickened (without myxoid degener-
ation), and a dilated annulus that is rarely calcified. In some
patients with degenerative mitral valve disease, the exact
etiology of valvular regurgitation remains undetermined.
The importance of a uniform method to identify patients
with mitral valve disease is best exemplified by comparing
the current study by Gillinov and colleagues1 in patients
with degenerative mitral valve disease and coexisting cor-
onary artery disease with another report by this group11
describing the durability of mitral valve repair in patients
Figure 1. Carpentier’s functional classification is based on the
opening and closing motions of the mitral leaflets. Type I has
normal motion of the leaflets and mitral regurgitation is on the
basis of the leaflet perforation or annular dilatation. In type II
dysfunction (increased leaflet motion) the free edge of the leaflet
travels above the plane of the mitral annulus during systole due
to chordal elongation or rupture. Type IIIa dysfunction implies
restricted opening leaflet motion during diastole and systole due
to rheumatic changes. Type IIIb dysfunction correlates to re-
stricted leaflet motion during systole secondary to papillary mus-
cle displacement.
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with isolated degenerative mitral disease. In the current
series (mean age 67 years, 73% male), annular dilatation is
not reported as an isolated mitral valve pathologic finding.
In contrast, the authors noted annular dilatation as the pri-
mary pathologic lesion in 16% of 1072 patients (mean age
58 years, 65% male) with degenerative mitral valve disease
undergoing isolated mitral valve repair between 1985 and
1997. It is unlikely that the mitral degenerative process
varies in patients with or without coexisting coronary artery
disease or that the mean age difference between the two
series explains the observed findings. We suspect a more
plausible explanation is a variance in their pathologic meth-
odology over time. We also take issue with the concept
presented by the authors “that elderly patients have more
advanced degenerative disease with more prolapse than do
younger patients with isolated mitral valve degeneration.”1
In our experience Barlow disease and Marfan disease are
usually associated with severe mitral regurgitation due to
multiple prolapsing leaflet segments and are more prevalent
in younger patients undergoing mitral valve surgery.
It is important to emphasize that the authors were very
careful to exclude patients with ischemic mitral regurgita-
tion in their study. Patients with this condition usually have
type IIIb dysfunction with leaflet restriction in systole, due
most commonly to papillary muscle displacement from
ventricular dilatation. Their long-term prognosis is signifi-
cantly worse than that of patients with degenerative mitral
valve disease.12-15 In the future, we advocate a more uni-
form adoption in the literature of classification of patients
with mitral valve disease according to valve dysfunctions,
lesions, and etiologies of disease. These precise distinctions
are relevant because the repair strategy depends on valve
dysfunction and lesions, whereas long-term prognosis de-
pends on etiology.
As is the case with many retrospective studies, some of
the reported findings are not particularly relevant since they
do not reflect current practice patterns. For example, the
authors observed replacement was more likely in older
patients with degenerative mitral valve disease. The safety
and efficacy of mitral valve repair in patients with advanced
age is now well documented in the literature.16,17 Similarly,
it is a safe bet that bileaflet prolapse is no longer associated
with a significantly increased incidence of replacement in
skilled mitral valve repair centers like The Cleveland Clin-
ic.2,3,11 One final caveat: we strongly disagree with the
concept of an algorithm to choose mitral valve surgical
strategy as presented by the authors in Figure 4 and Appen-
dix 2. “Replacement benefit” is an oxymoron in patients
with degenerative mitral valve disease. The only consider-
ation in degenerative mitral regurgitation for repair or re-
placement should be the surgeon’s ability to achieve a
successful repair. There may be isolated patients with ad-
vanced left ventricular dysfunction or other comorbidities in
whom the survival benefit of a mitral valve repair is not
obvious; however, it is important to emphasize the authors
did not assess the quality of valve repair, quality of life, left
ventricular function over time, valve-related complications,
valve durability, or reoperation in this study.
The methodology of data analysis was complex, and the
authors deserve substantial praise for a statistical tour de
force to demonstrate the benefit of mitral valve repair in
patients with degenerative disease and concomitant coro-
nary artery disease. They have provided further evidence
that our patients deserve our best effort to preserve the
native mitral valve whenever possible.
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